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Respiratory Tract Specimens in the Setting of a Tertiary
Care Academic Medical Center
Daniel M. Webber,a Meghan A. Wallace,a Carey-Ann D. Burnham,a Neil W. Andersona
aDivision of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri,
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ABSTRACT Our objective was to evaluate the diagnostic yield and accuracy of the
BioFire FilmArray pneumonia panel (BFPP) for identification of pathogens in lower
respiratory tract specimens (n  200) from emergency department (ED) and intensive
care unit (ICU) patients at a tertiary care academic medical center. Specimens were
collected between January and November 2018, from patients 18 years of age, and
culture was performed as part of standard-of-care testing. The BFPP identified a viral
or bacterial target in 117/200 (58.5%) samples, including Staphylococcus aureus in
22% of samples and Haemophilus influenzae in 14%, and both a viral and bacterial
target in 4% of samples. The most common viruses detected by BFPP were rhinovi-
rus/enterovirus (4.5%), influenza A virus (3%), and respiratory syncytial virus (RSV)
(2%). Overall, there was strong correlation between BFPP and standard methods for
detection of viruses (99.2%) and bacteria (96.8%). Most bacteria (60/61 [98.4%]) de-
tected by standard methods were also identified by BFPP, and 92 additional bacteria
were identified by BFPP alone, including 22/92 (23.9%) additional S. aureus isolates
and 25/92 (27.2%) H. influenzae isolates, which were more frequently discordant
when detected at low concentrations (S. aureus, P  0.001; H. influenzae, P  0.0001)
and in sputum-type specimens (S. aureus, P  0.05). A potential limitation of the
BFPP assay is the absence of fungal targets and Stenotrophomonas maltophilia,
which were detected in 26 and 4 of 200 specimens, respectively. Real-time specimen
analysis with BFPP has the potential to identify bacterial pathogens and resistance
markers 44.2 and 56.3 h faster than culture-based methods. The BFPP is a rapid and
accurate method for detection of pathogens from lower respiratory tract infections.
KEYWORDS BioFire, quantitative PCR, syndromic testing, pneumonia
Pneumonia is one of the most common causes of hospitalization in the United Statesand is one of the leading causes of death worldwide (1; www.hcup-us.ahrq.gov/
faststats/landing.jsp). For bacterial pneumonia, prompt treatment with antibiotics can
improve outcomes, and delay in effective antimicrobial therapy is associated with
increased mortality and length of hospital stay (2–4). Current guidelines recommend
empirical use of antimicrobial therapy among patients with suspected pneumonia (5).
While empirical antibiotics are critical for patients with pneumonia, the extensive use of
antibiotics among patients with respiratory conditions threatens to erode the efficacy
of these medications. Recent estimates suggest that half of antibiotic prescriptions for
acute respiratory conditions are unnecessary, primarily in the setting where antibiotics
are given for viral infections (6). Unnecessary antibiotic use has led to a rise in number
of antibiotic-resistant infections, which now affect over 2.8 million people each year
and result in over 35,000 deaths annually (7). Rapid diagnostic testing for pneumonia
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has the potential to guide clinical decisions and reduce the use of broad-spectrum
antibiotics; however, these benefits are dependent upon the accuracy of these test
methods.
The BioFire FilmArray pneumonia panel (BFPP) was recently FDA cleared (November
2018) for detection and identification of multiple respiratory viral and bacterial patho-
gens in addition to selected antimicrobial resistance genes from sputum or bronchial
alveolar lavage (BAL)-like specimens from individuals with suspected lower respiratory
tract (LRT) infections. This assay includes targets for 18 bacteria and 8 viruses that
commonly cause pneumonia as well as 7 antibiotic resistance genes. The BFPP assay
reports the presence or absence of 3 atypical bacteria and provides a semiquantitative
organism abundance for the other 15 bacteria, analogous to the semiquantitative
reporting provided with traditional culture-based testing. Although this is a novel and
potentially useful feature for a PCR-based method, data on the correlation of this
method with conventional cultures are scarce, and it is yet unknown how these results
might be interpreted and acted upon clinically.
The objective of our investigation was to evaluate the performance characteristics
and potential clinical impact of the BFPP in the context of a large academic medical
center.
(This study was presented in part at the June 2019 ASM Microbe meeting in San
Francisco, CA [presentation number AAR-725], and at the May 2019 Academy of Clinical
Laboratory Physicians and Scientists annual meeting in Salt Lake City, UT.)
MATERIALS AND METHODS
Sample selection. This study was conducted at Barnes Jewish Hospital, a 1,250-bed, tertiary care,
academic medical center located in St. Louis, MO. Following approval from the Institutional Review Board
(IRB) of Washington University in St. Louis, consecutively available samples were enrolled and frozen at
– 80°C based on the following inclusion criteria: (i) an aerobic lower respiratory bacterial culture was
ordered and performed as part of standard-of-care (SOC) testing, (ii) the specimen was acceptable for
culture based on specimen type Gram stain criteria, (iii) the sample was stored at refrigerator temper-
atures for 24 h prior to freezing, (iv) adequate residual volume (1.5 ml) was available from aerobic
culture, and (v) a lower respiratory sample was collected in the emergency department (ED) or intensive
care unit (ICU) or from a patient care unit with immunocompromised patients at Barnes-Jewish Hospital
(Fig. 1). Patients were excluded from the study based on the following criteria: (i) having a previous
sample included in the study within 14 days, (ii) the patient was 18 years of age, (iii) clinical information
FIG 1 Study design. A total of 200 consecutively available lower respiratory tract samples were collected between
January and November 2018. Samples were from adult patients with respiratory symptoms at a large tertiary care
academic medical center. Remnant samples were stored at – 80°C prior to being tested with the BFPP on the BioFire
FilmArray 2.0. Antibiotic utilization and standard-of-care test results were obtained by retrospective chart review,
and these data were used to determine turnaround time and test performance characteristics.
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was not available for the patient (i.e., immediately transferred to different institution), and (iv) the patient
did not meet eligibility criteria as outlined above. A total of 265 patients were screened for eligibility
between January and November 2018; 200 samples from 198 patients were eligible. Specimen aliquots
were stored at 4°C for no more than 1 day prior to being frozen at – 80°C in preparation for testing.
Aliquots were frozen for a range of 71 to 213 days before being thawed and analyzed by the BFPP.
Aliquots were coded and assigned a study number by an honest broker. We use the term standard of
care to refer to real-world clinical data from tests that are routinely ordered in our facility for the care of
individuals with suspected lower respiratory illness. We acknowledge that the standard of care may vary
by region and clinical setting and that this represents real-world clinical data from our specific setting.
BioFire FilmArray pneumonia panel. Frozen (– 80°C) lower respiratory tract (LRT) specimens were
analyzed on the BioFire FilmArray 2.0 using the BioFire FilmArray pneumonia panel. Testing was
performed in accordance with the manufacturer’s instructions in a single research laboratory by qualified
personnel. In brief, the BioFire pouch was removed from packaging, inserted into the pouch loading
station, and hydrated with the manufacturer-supplied hydration solution. The BAL-like or sputum-like
specimen was then mixed with sample buffer and was injected into the BioFire pouch. The pouch was
scanned and loaded into the BioFire FilmArray 2.0, and the run was initiated. The BFPP includes two
process controls in each pouch, which must both be positive for a run to pass. Runs that failed these
internal process controls in our study were repeated with a new pouch. In the event of an invalid or
indeterminate result, specimen testing was repeated once. BFPP results were for internal study purposes
only and were not reported to members of the patient’s care team.
Bacterial culture. Bacterial cultures were performed as part of SOC testing in the Clinical Microbi-
ology Laboratory at Barnes-Jewish Hospital.
Sputum. Sputum specimens were evaluated by unconcentrated conventional Gram stain prior to
plating. Specimens with over 10 epithelial cells per low-power field on conventional Gram stain were
considered to have excessive oral flora. These samples were rejected and culture was not performed,
making these specimens ineligible for inclusion in this study. On average, 30% of sputum specimens
submitted to the laboratory are rejected based on Gram stain characteristics. Acceptable sputum
specimens were plated on Trypticase soy agar with 5% sheep blood (BAP), chocolate agar (CHOC), and
MacConkey agar (MAC) from Remel (Lenexa, KS), were streaked for isolation using the quadrant streak
method, and were incubated at 35°C in 5% CO2. All plates were examined for growth at 24 h of
incubation. MAC plates without growth at 18 to 24 h were discarded. BAP and CHOC plates were
reexamined at 48 h and were discarded at that time. Bacterial growth from sputum samples was reported
qualitatively based on the following criteria: “rare,” 10 colonies or fewer in the first quadrant; “few,”
greater than 10 colonies in the first quadrant; “moderate,” greater than 10 colonies and growth into the
second quadrant; and “abundant,” heavy growth of colonies in the second quadrant, leading to growth
into the third or fourth quadrant. Pathogens with a potential to be respiratory microbiota, such as
Haemophilus influenzae and Streptococcus pneumoniae, were reported only if they were present in
moderate to abundant quantities or if they were the predominant organism. Cultures were reported as
“upper respiratory flora” if only normal upper respiratory microbiota were isolated in the absence of
significant pathogens.
Tracheal aspirate. Tracheal aspirate specimens were evaluated by unconcentrated conventional
Gram stain prior to plating. Samples were inoculated onto BAP, CHOC, and MAC plates using a
cross-streak pattern with a 0.001-ml calibrated loop and were incubated at 35°C in 5% CO2. All plates
were examined for growth at 24 h of incubation. MAC plates without growth at 18 to 24 h were
discarded. BAP and CHOC plates were reexamined at 48 h and were discarded at that time. Pathogens
with a potential to be respiratory microbiota, such as H. influenzae and Streptococcus pneumoniae, were
worked up for identification and susceptibility testing if isolated at or above 1  105 colonies (col)/ml.
Growth of bacterial isolates above this threshold amount were reported as 100,000 col/ml. Isolates
present at fewer than 1  105 col/ml were reported as “insignificant growth.” Cultures were reported as
“upper respiratory flora” if only normal upper respiratory microbiota were isolated in the absence of
significant pathogens.
Bronchial alveolar lavage and bronchial washing. Acceptable BAL-type specimens (bronchial
wash and bronchial alveolar lavage) were concentrated by Cytospin and then evaluated by conventional
Gram stain. Specimens were inoculated onto BAP, CHOC, and MAC plates using a cross-streak pattern
with a 0.001-ml calibrated loop and were incubated at 35°C in 5% CO2. All plates were examined for
growth at 24 h of incubation. MAC plates without growth at 18 to 24 h were discarded. BAP and CHOC
plates were reexamined at 48 h and were discarded at that time. Pathogens with a potential to be
respiratory microbiota, such as H. influenzae and Streptococcus pneumoniae, were worked up for identity
and susceptibility if isolated at 1  103 col/ml for a BAL specimen or 1  104 col/ml for a bronchial
washing. Bacterial isolates quantified below these thresholds were reported as “insignificant growth.”
Growth at concentrations above these thresholds was reported semiquantitatively as either 1,000
col/ml, 10,000 to 100,000 col/ml, or 100,000 col/ml for BAL samples or as 10,000 to 100,000 col/ml or
100,000 col/ml for bronchial washing samples. Cultures were reported as “upper respiratory flora” if
only normal upper respiratory microbiota were isolated in the absence of a significant pathogen.
All specimen types. Isolated bacterial colonies were identified with a combination of spot biochem-
ical testing (e.g., catalase, oxidase) and matrix-assisted laser desorption/ionization–time of flight mass
spectrometry (MALDI-TOF MS) using the Bruker Biotyper. Alpha-hemolytic colonies were screened with
bile solubility reagent (sodium deoxycholate) or P-disk (optochin) to rule out Streptococcus pneumoniae.
Susceptibility testing was performed by a combination of disk diffusion and gradient diffusion method-
ologies in accordance with CLSI standards, and results were interpreted using current CLSI interpretive
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criteria (8, 9). S. aureus isolates were classified as either methicillin-resistant (MRSA) or methicillin-
susceptible (MSSA) based on the Alere PBP2a SA culture colony test (Abbott Laboratory, Chicago, IL) and
disk diffusion testing with cefoxitin (8). The Cepheid (Sunnyvale, CA) Xpert Carba-R assay was used as part
of SOC testing for detection and differentiation of blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP from
isolated colonies of Enterobacterales, which tested intermediate or resistant to any carbapenem tested
and were positive by modified carbapenemase inactivation method (mCIM) testing (8). Other SOC test
results were included in the study if the testing was ordered 48 h prior to or 48 h after ordering of the
bacterial culture. SOC result reporting was performed in real time per the clinical laboratory’s standard
operating procedure.
Viral detection. SOC testing for influenza A virus, influenza B virus, and respiratory syncytial virus
(RSV) was performed using the Cepheid Xpert Xpress Flu/RSV assay. Herpes simplex virus (HSV),
cytomegalovirus (CMV), and adenovirus were detected by PCR performed on a Diasorin Liaison MDX
(Cypress, CA). Biofire respiratory panel V2.0 (RP2) was performed on the BioFire FilmArray Torch with
either nasopharyngeal (NP) samples (according to manufacturer’s guidelines) or LRT samples (performed
off-label following verification within our laboratory). Each LRT sample was mixed with BioFire sample
buffer and was injected into an RP2 pouch by means of the BioFire pouch loading station. The BioFire
respiratory viral panel V2.0 includes targets for the following viruses and bacteria: adenovirus, corona-
virus (HKU1, NL63, 229E, and OC43), human metapneumovirus, human rhinovirus/enterovirus, influenza
viruses (A/H1, A/H3, A/H1-2009, and B), parainfluenza virus (1 to 4), RSV, Bordetella pertussis, Bordetella
parapertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae. All SOC viral test results, including
results from BioFire RP2, were reported to clinicians in real time and were collected retrospectively as part
of this study.
Other testing. Several other tests were ordered as part of SOC on a subset of the specimens,
including fungal culture, acid-fast bacillus (AFB) culture, Legionella culture, Legionella urine antigen
testing, and direct fluorescent antibody (DFA) staining for Pneumocystis. Legionella culture was per-
formed by streaking specimen onto a buffered charcoal-yeast extract agar (BCYE) plate from BD (Franklin
Lakes, NJ) and a buffered charcoal-yeast extract agar plate with polymyxin B, anisomycin, and vanco-
mycin (BCYE/PAV) (Remel). Plates were incubated in air at 35ŒC and were examined for growth at 3, 5,
and 7 days; presumptive Legionella isolates were submitted to the Missouri State Public Health Labora-
tory for confirmation. Legionella urine antigen testing was performed using the Binaxnow Legionella
urinary antigen card from Abbott (Abbott Park, IL). DFA staining for Pneumocystis jirovecii was performed
using an immunofluorescence test kit from Bio-Rad (Hercules, CA). Any positive blood culture results
within 5 days of the BFPP testing were also recorded as part of the chart review.
Detection of microbial species within a microorganism complex. We evaluated the potential of
the BFPP to detect closely related species using prepared suspensions of bacteria, including Klebsiella
variicola and Staphylococcus argenteus, by preparing a fresh subculture of clinical isolates. After 18 to 24
h of incubation at 37°C, isolates were inoculated into sterile saline to make a 0.5 McFarland suspension.
The McFarland suspension was diluted 1:100 in saline and was run as a BAL specimen according to the
package insert for the BFPP.
Chart review and statistics. Study data, including antibiotic utilization and SOC test results, were
collected by retrospective chart review using a REDCap (Research Electronic Data Capture) data collec-
tion instrument that was designed as part of this study (see Table S1 in the supplemental material); the
RedCap database and tools were hosted at the Institute for Informatics at Washington University School
of Medicine (10). Data were analyzed in GraphPad Prism version 8.2.1 (GraphPad, San Diego, CA) using
parametric two-sided t test, chi-square test, and least-squares linear regression.
RESULTS
Patient population. The mean age of study subjects was 57.7 years (range, 18 to
89 years); most subjects were men (62.8%) being treated on a critical care floor (93.5%)
and presenting for medical care primarily during the winter (29%) and spring (54.5%)
seasons. Nearly half of subjects (95/200 [47.5%]) had an onset of respiratory symptoms
prior to or within 48 h of admission. Nearly two-thirds of subjects (129/200 [64.5%])
were on a ventilator for at least 24 h prior to aerobic culture collection, and one-third
of subjects (66/200 [33.3%]) were reported as deceased within 30 days of sample
collection (Table 1).
Overview of BFPP results by specimen type. BFPP detected bacteria exclusively in
44.5% (89/200) of samples, viruses exclusively in 10% of samples (20/200), and co-
occurring bacteria and viruses in 4% (8/200) of samples (Fig. 2). There was no significant
difference (P  0.36) in the number of viruses and bacteria detected by BFPP in
sputum-type samples (sputum and tracheal aspirates; n  130) compared to BAL-type
specimens (BAL fluid and bronchial wash; n  70). Nearly half of positive samples
(50/117) contained more than one viral or bacterial target.
Viral detection. We next evaluated BFPP test performance characteristics by com-
paring results from BFPP to those obtained by SOC viral testing. We observed a high
overall agreement (overall accuracy; mean, 95% confidence interval [CI]) (99.2% [98.4%,
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99.6%]) between these two methods for viral detection; however, positive agreement
between methods was lower than expected (82.6% [62.9%, 93.0%]) due to four cases
in which a virus was detected by the SOC BioFire RP2 but not by BFPP. These discordant
results included two for coronavirus HKU1, one for adenovirus, and one for influenza A
TABLE 1 Population demographics
Characteristic
Sample type
BAL type Sputum type Total
No. Category % No. Category % No. Category %
Sexa
Female 29 41.4 45 34.9 74 37.2
Male 41 58.6 84 65.1 125 62.8
Age (yrs)
18–34 9 12.9 14 10.8 23 11.5
35–65 36 51.4 81 62.3 117 58.5
65 25 35.7 35 26.9 60 30.0
Setting
ICU/oncologyb 69 98.6 118 90.8 187 93.5
Emergency department 1 1.4 12 9.2 13 6.5
Season
Winter (December–February) 16 22.9 42 32.3 58 29.0
Spring (March–May) 40 57.1 69 53.1 109 54.5
Summer (June–August) 2 2.9 12 9.2 14 7.0
Fall (September–November) 12 17.1 7 5.4 19 9.5
Hosp onsetc
Yes 36 51.4 69 53.1 105 52.5
No 34 48.6 61 46.9 95 47.5
Ventd
Yes 46 65.7 83 63.8 129 64.5
No 24 34.3 47 36.2 71 35.5
30-day mortalitye
Yes 20 28.6 46 35.4 66 33.0
No 46 65.7 77 59.2 123 61.5
Unknown 4 5.7 7 5.4 11 5.5
Row total 70 35.0 130 65.0 200 100.0
aGender information was unavailable for one of the study participants.
bIncluding 180 ICU patients and 7 oncology patients on an immunocompromised patient floor.
cOnset of respiratory symptoms 48 h after admission to the hospital (Hosp).
dIntubated with ventilator support for 24 h prior to aerobic culture.
eDeath within 30 days of aerobic culture specimen collection.
FIG 2 BFPP detection. Panel a shows that BFPP detected a bacterium or virus in 117/200 (58.5%) of samples, with
similar distributions between sample types (P  0.36 [chi-square test] and degrees of freedom [df]  3). Panel b
demonstrates that more than one pathogen was detected by BFPP in 50/116 (43%) of positive samples.
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virus (Table 2 and Fig. 3). In three cases, the same sample was used for both SOC and
retrospective viral testing (Table 3), and a different sample was used in the fourth case
in which a coronavirus was detected by SOC RP2 but not by BFPP. For three of these
cases, it was possible to compare results with RP2 testing that had been undertaken
earlier or later in the hospital course (date of aerobic culture collection  5 days). Only
one of the SOC-positive, BFPP-negative results was positive at a second time point; this
case was also positive for the same target (influenza A virus; cycle threshold [CT], 34.8)
when tested retrospectively using the Cepheid Xpert Flu/RSV Xpress assay. The other
two discrepant cases had negative results from RP2 testing 2 h earlier (tracheal
aspirate negative, subsequent BAL positive for coronavirus) and 4 days earlier
(initial BAL negative, subsequent BAL positive for coronavirus), respectively. The
percent positive agreement (PPA) between the remaining five viral targets on the BFPP
was 100% (Table 2).
A virus was detected by BFPP but not by SOC in an additional three cases. These
discordant viral results were for influenza A virus, coronavirus, and parainfluenza virus
(Table 3). Of note, BFPP detected a viral target in an additional nine cases (4.5% of
specimens) where there was no SOC testing for the virus within a 96-h period before
or after aerobic culture. In contrast, SOC testing detected a virus that was not on the
BioFire panel in nine cases (4.5%), including five cases with herpes simplex virus (HSV)
and four cases with cytomegalovirus (CMV).






SOC-NTProp.a % 95% CId (%) Prop. % 95% CId (%)
Viruses
Rhinovirus/enterovirus 5/5 100 56.6–100 103/103 100 96.4–100 4 88
Influenza A virus 4/5 80 37.6–99.0 104/105 99.0 94.8–99.9 1 89
Coronavirus 1/3 33.3 1.7–88.2 106/107 99.1 94.9–99.9 1 91
Influenza B virus 3/3 100 43.9–100 107/107 100 96.5–100 1 89
RSV 4/4 100 51.0–100 106/106 100 96.5–100 0 90
Metapneumovirus 1/1 100 5.1–100 107/107 100 96.5–100 2 90
Parainfluenza virus 1/1 100 5.1–100 106/107 99.1 94.9–99.9 0 92
Adenovirus 0/1 0 0–94.9 107/107 100 96.5–100 0 92
Total 19/23 82.6 62.9–93.0 846/849 99.5 99.0–99.9 9 721
Bacteria
Staphylococcus aureus 22/22 100 85.1–100 156/178 87.6 82.0–91.7 0 0
Haemophilus influenzae 3/3 100 43.9–100 172/197 87.3 81.9–91.3 0 0
Pseudomonas aeruginosa 8/8 100 67.6–100 185/192 96.4 92.7–98.2 0 0
Enterobacter cloacae complex 3/4 75 30.1–98.7 189/196 96.4 92.8–98.3 0 0
Escherichia coli 6/6 100 61.0–100 190/194 97.9 94.8–99.2 0 0
Streptococcus pneumoniae 2/2 100 17.8–100 191/198 96.5 92.9–98.3 0 0
Klebsiella pneumoniae group 4/4 100 51.0–100 192/196 98.0 94.9–99.2 0 0
Streptococcus agalactiae 2/2 100 17.8–100 193/198 97.5 94.2–98.9 0 0
Klebsiella aerogenes 2/2 100 17.8–100 196/198 99.0 96.4–99.8 0 0
Klebsiella oxytoca 3/3 100 43.9–100 196/197 99.5 97.2–99.9 0 0
Moraxella catarrhalis 1/1 100 5.1–100 196/199 98.5 95.7–99.6 0 0
Proteus spp. 0/0 NAe NA 196/200 98.0 95.0–99.2 0 0
Serratia marcescens 3/3 100 43.9–100 197/197 100 98.1–100 0 0
Acinetobacter baumannii–calcoaceticus complex 0/0 NA NA 199/200 99.5 97.2–99.9 0 0
Legionella pneumophila 0/0 NA NA 44/44 100 92.0–100 1 156
Mycoplasma pneumoniae 1/1 100 5.1–100 86/86 100 95.7–100 0 80
Total 60/61 98.4 91.3–99.9 2778/2870 96.8 96.1–97.4 1 236
aProp., proportion for positive percent agreement (PPA) or negative percent agreement (NPA), calculated as follows: PPA  concordant positive/all positive results by
SOC, and NPA  concordant negative/all negative results by SOC.
bBFPP-pos, SOC-NT, analyte detected by BFPP but not tested by standard of care.
cSOC testing also detected herpes simplex virus (n  5), cytomegalovirus (n  4), Stenotrophomonas maltophilia (n  4), Acinetobacter spp. (n  1), Citrobacter freundii
complex (n  1), Klebsiella variicola (n  1), and Staphylococcus intermedius group (n  1), which are not included in the BFPP panel. SOC testing detected yeast or
mold in an additional 26 samples, including 21 yeasts, 2 Aspergillus spp., 1 Blastomyces dermatitidis/B. gilchristii isolate, 1 Paecilomyces species, and 1 Pneumocystis
jirovecii isolate.
dCI, confidence agreement for a binomial distribution, calculated by the Wilson/Brown method.
eNA, not applicable.
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Bacterial detection. Overall agreement between BFPP and SOC for detection and
identification of bacteria was 96.8% (96.1%, 97.4%). Likewise, we observed a high PPA
for bacterial detection, 98.4% (91.3%, 99.9%) (Table 2). An on-panel bacterium (Entero-
bacter cloacae complex) was detected by SOC but not by BFPP in only one case. An
additional eight samples (4%) grew bacteria that were not part of the BFPP panel,
including four Stenotrophomonas maltophilia isolates, one non-baumannii-complex
FIG 3 Concordance of BFPP with standard of care (SOC) for viral and bacterial identification. Panel a shows a high
overall agreement (99%) of BFPP with SOC for detection of viruses. Panel b shows a predominance of S. aureus and
H. influenzae among detected bacterial targets and displays 92 bacterial targets detected by BFPP and not by SOC
testing.
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Acinetobacter sp., one Citrobacter freundii complex isolate, one Staphylococcus interme-
dius group isolate, and one Klebsiella variicola isolate. Two bacteria from the BFPP panel,
Chlamydia pneumoniae and Streptococcus pyogenes, were not detected in this cohort by
either SOC or BFPP.
BFPP also showed a high negative percent agreement (NPA) with results from
aerobic culture. NPA for bacterial identification was 96.8% (96.1%, 97.4%). Two bacteria,
S. aureus and H. influenzae, had an NPA of less than 90%. These organisms accounted
for over half of the 92 bacteria that were detected by BFPP alone, including 22 S. aureus
and 25 H. influenzae isolates that were detected only by BFPP, compared to 22 S. aureus
and 3 H. influenzae isolates that were detected concordantly. NPA was greater than 90%
for the remaining bacteria; however, the number of discordant bacterial detections
exceeded the number of concordant detections (noted as discordant: concordant in the
following passage) for Enterobacter cloacae complex (7:3), Streptococcus pneumoniae
(7:2), Streptococcus agalactiae (5:2), Proteus spp. (4:0), and Moraxella catarrhalis (3:1).
SOC testing detected yeast or mold in an additional 26 samples, including 21 yeasts, 2
Aspergillus spp., 1 Blastomyces dermatitidis/Blastomyces gilchristii isolate, 1 Paecilomyces
species, and 1 Pneumocystis jirovecii isolate.
Detection of S. aureus and determination of antimicrobial resistance. Twenty-
two additional S. aureus were detected by BFPP alone, including 15 MSSA and 7 MRSA
isolates that were positive for mecA/C and MREJ (Table 4). For the majority of cases with
discordant S. aureus results (15/22 [68.2%]), the subject was on effective antibiotics
(based on hospital antibiogram and BFPP mecA/C status) at the time of aerobic culture,
reflecting the widespread use of antibiotics in this population (149/200 [74.5%] of
patients on 1 antibiotic at the time of aerobic culture). BFPP also identified MRSA in
TABLE 3 Details on discordant viral test resultsa





collection times (h)BFPP SOC
1 Coronavirus SOC RP2, BFPP BAL BAL No 34:35
2 Coronavirus SOC RP2, BFPP BAL BAL Yes NA
3 Adenovirus SOC RP2, BFPP Tracheal aspirate Tracheal Aspirate Yes NA
4 Influenza A virusb SOC RP2, BFPP Tracheal aspirate Tracheal aspirate Yes NA
5 Influenza A virus BFPP, SOC RP2 BAL BAL Yes NA
6 Coronavirus BFPP, SOC RP2 Sputum BAL No 9:25
7 Parainfluenza virus BFPP, SOC RP2 Tracheal aspirate Tracheal aspirate Yes NA
aThe Biofire respiratory panel V2.0 (RP2) was performed for each of the lower respiratory tract (LRT) samples included as a laboratory-developed test.
bSpecimen retrospectively positive for influenza A virus by Xpert Flu/RSV Xpress assay (cycle threshold [CT], 34.8).
TABLE 4 S. aureus identification and susceptibility by sample typea
Sample type and BFPP result
SOC aerobic culture
MRSA MSSA S. aureus neg.
Sputum typeb
MRSA 3 3 7
MSSA 0 7 12
S. aureus neg. 0 0 98
BAL typec
MRSA 5 1 0
MSSA 0 3 3
S. aureus neg. 0 0 58
Overall
MRSA 8 4 7
MSSA 0 10 15
S. aureus neg. 0 0 156
aMRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; neg.,
negative.
bSputum-type specimens include sputum (n  54) and tracheal aspirate (n  76).
cBAL-type specimens include bronchoalveolar lavage fluid (BAL) (n  59) and bronchial washing (n  11).
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four cases where SOC testing reported MSSA, including one discordant result in
BAL-type specimens and three discordant results among sputum-type specimens
(Table 4), resulting in a moderately decreased NPA for both BAL-type (75% [30.1%,
98.7%]) and sputum-type (70% [39.7%, 89.2%]) specimens. These four additional MRSA
detections by BFPP were from polymicrobial samples.
BFPP detected Gram-negative antimicrobial resistance (AMR) genes in eight samples
(Table 5). Six of these samples were positive for only blaCTX-M, one sample was positive
for both blaCTX-M and blaKPC, and an additional sample was positive for only blaKPC
based on BFPP results. BFPP detected all four cases with AMR reported by SOC (overall
PPA: 100%) as well as an additional three cases (three blaCTX-M) that were not evaluated
for AMR by SOC because suspect bacteria were not present at threshold levels in
culture, including one sample with Enterobacter cloacae complex (107 copies/ml by
BFPP), one sample with Escherichia coli (106 copies/ml) and Klebsiella pneumoniae group
(105 copies/ml), and one sample with Klebsiella pneumoniae group (104 copies/ml)
reported by BFPP alone. Overall, 4/7 (57.1%) samples were from subjects with putative
mecA/C and MREJ, who were on optimal antimicrobial regimens, and 1/3 (33.3%) of
samples were from subjects with blaCTX-M who were receiving appropriate antibiotics
at the time of culture.
One of the two samples that were positive for blaKPC by BFPP was not evaluated for
antimicrobial resistance by SOC because detected bacteria were below the threshold
for workup and reporting for tracheal aspirates. In this case, aerobic culture reported
yeast (100,000 col/ml) plus growth of clinically insignificant bacterial flora
(1  105 col/ml), whereas BFPP identified Enterobacter cloacae complex (104 copies/
ml) and Pseudomonas aeruginosa (107 copies/ml). A carbapenem-susceptible Entero-
bacter cloacae complex was also reported on SOC blood cultures from the previous
day, along with vancomycin-resistant Enterococcus faecium; blood cultures were neg-
ative when repeated the day after aerobic cultures were taken. This patient was
discharged 8 days later in stable condition on meropenem and daptomycin but expired
within the following 10 days due to unreported causes.
Factors related to discordant bacterial detection. We examined factors that
might predict S. aureus and H. influenzae discordance for SOC versus BFPP, including
bacterial quantity from BFPP, rare or no polymorphonuclear leukocytes (PMNs) on
Gram stain (marker for suboptimal specimens), abundant squamous epithelium on
Gram stain (marker of oropharyngeal contamination), sputum or tracheal aspirate
sample type, and empirical antibiotic coverage of detected bacteria (e.g., MRSA, MSSA,
or H. influenzae). Least-squares regression was used to fit these covariates to a linear
TABLE 5 BFPP performance characteristics for detection of AMR compared with SOC methods
Analytea
PPA NPA Discordant bacterial ID





mecA/C or MREJe 8/8 100 67.6–100 10/14 71.4 45.3–88.3 7 0
CTX-Mf 4/4 100 51.0–100 24/24 100 86.2–100 3 0
IMP 0/0 NA NA 29/29 100 88.3–100 0 0
KPCg 1/1 100 5.1–100 28/28 100 87.9–100 1 0
NDM 0/0 NA NA 29/29 100 88.3–100 0 0
VIM 0/0 NA NA 29/29 100 88.3–100 0 0
OXA-48-like 0/0 NA NA 21/21 100 84.5–100 0 0
aDisk diffusion testing was used as an initial SOC method for evaluating antimicrobial resistance (AMR).
bFractional proportion (Prop.) of PPA or NPA, expressed as follows: PPA  concordant positive/all positive results by SOC, and NPA  concordant negative/all
negative results by SOC.
cBFPP positive for AMR gene; SOC AMR was not tested (NT) because of discordant identification of bacteria by BFPP alone.
dThere were no cases where SOC AMR was positive and BFPP AMR was not tested.
emecA/C status was determined by disk diffusion testing (cefoxitin resistance) and positive results on Alere™ PBP2a SA culture colony test (Abbott).
fPhenotypic evidence of extended-spectrum-beta-lactamase (ESBL) production on SOC disk diffusion testing was considered for the purposes of the table as
concordant with CTX-M detection by BFPP.
gKPC status was determined for SOC samples using Cepheid Xpert.
hCI, confidence agreement for a binomial distribution, calculated by the Wilson/Brown method.
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model. Multivariate analysis showed that low S. aureus quantity (P  0.0019 and
Pearson’s r  0.49) and sputum/tracheal aspirate sample type (P  0.03 and Pearson’s
r  0.13) were associated with discordant detection by BFPP (model fit:
r-squared  0.35 and degrees of freedom  37) (Table S2 and Fig. S3). Gram stain PMNs
(P  0.63), squamous epithelium quantity (P  0.63), and empirical coverage for S.
aureus (P  0.29) were not significantly associated with discordant detection of S.
aureus. Similar to results from S. aureus, a low quantity of H. influenzae (P  0.0001 and
Pearson’s r  0.74) organisms was associated with discordant detection of H. influ-
enzae by BFPP (Fig. 4) (model fit: r-squared  0.57 and degrees of freedom  21), such
that concordant results for H. influenzae were only detected at 107 copies/ml as
measured by BFPP. Unlike with S. aureus, concordant detection of H. influenzae was not
associated with specimen type. PMNs (P  0.98), squamous epithelium quantity
(P  0.27), and empirical coverage for H. influenzae (P  0.09) were not significantly
associated with discordant detection of H. influenzae (Table S2 and Fig. S3).
Detection of microorganisms within an organism complex. By running organism
suspensions in pure cultures of Klebsiella variicola (member of the Klebsiella pneu-
moniae group) and S. argenteus (member of the S. aureus complex), we were able to
determine the potential for BFPP to detect these clinically important species. Testing
showed that 3/3 (100%) Klebsiella variicola isolates were identified as Klebsiella pneu-
moniae group. Likewise, 1/1 (100%) of Staphylococcus schweitzeri and 2/2 (100%) S.
argenteus isolates were identified by the BFPP as the closely related species S. aureus.
FIG 4 Discordant detection of S. aureus and H. influenzae by bacterial quantity (left) and specimen type
(right). Multivariate, least-squares, linear regression demonstrates that S. aureus (a and b) and H.
influenzae (c and d) quantity as measured by BFPP was directly and independently associated with
concordant detection by BFPP and SOC culture, compared to detection by BFPP alone (S. aureus model,
r-squared  0.35 and df  37; H. influenzae model, r-squared  0.57 and df  21). P values from regres-
sion coefficients are represented as follows: ***, P  0.001; **, P  0.01; *, P  0.05; and ns, nonsignificant.
Values inside columns represent the number of samples per horizontal-axis category as grouped by test
concordance.
Webber et al. Journal of Clinical Microbiology
July 2020 Volume 58 Issue 7 e00343-20 jcm.asm.org 10
 on A











Turnaround time comparison. The BFPP has a turnaround time (TAT) and workflow
considerations similar to those for the SOC BioFire RP2. Therefore, the TAT from RP2
testing that was performed as part of SOC for a subset of subjects in this study (n  95)
was used as a surrogate for turnaround time estimation for BFPP. Organism identifi-
cation was, on average, 42.2 h faster with the BFPP surrogate than with SOC
(P  0.0001, 2-tailed, unpaired t test). Likewise, the turnaround time for detection of
AMR markers by the BFPP surrogate was shorter (56.3-h reduction; P  0.0001) than
determination of antimicrobial susceptibility by standard phenotypic methods (Fig. 5).
Clinical outcomes. If BFPP were detecting clinically significant infections missed by
SOC (true positive), one would expect worse clinical outcomes among these undiag-
nosed patients. Therefore, we used one-way analysis of variance (ANOVA) to test for a
difference in length of hospital stay, and we applied a two-sided Fisher’s exact test to
test for differences in 30-day mortality between these otherwise similar patient groups
(Table S2). Analysis demonstrated that length of hospital stay and 30-day mortality,
as measured from time of aerobic culture, were not significantly different (P  0.05)
for patients with concordant versus discordant S. aureus and H. influenzae detection
(Fig. 6).
DISCUSSION
This study evaluated the BFPP in the setting of a large, academic medical center. Our
results demonstrate that the BFPP is a rapid method for identifying pathogens and
resistance markers in patients with suspected pneumonia. Our data show that a
bacterial pathogen was detected in a high proportion of samples (48.5%) from our
patient cohort, likely reflective of our inclusion criteria. Fourteen percent of samples
were positive for viral targets, including 8 specimens (4%) with bacterial-viral codetec-
tion. Bacterial codetection was identified in more than a quarter (28.6%) of cases in
which a virus was detected by BFPP. These results are comparable with the incidence
of bacterial-viral coinfection reported elsewhere (11–13).
We report a high overall agreement between BFPP and SOC for detection of bacteria
and viruses. However, we also note that BFPP detects additional bacteria, including S.
aureus and H. influenzae, that are not reported by SOC. We show that these BFPP-only
detections are more common among samples with a low concentration of bacteria as
well as among sputum-type samples than among BAL-type specimens.
The BFPP demonstrated high negative percent agreement (NPA) compared to SOC
viral detection, suggesting high clinical specificity. However, the average positive
percent agreement (PPA) for BFPP viral testing was lower, at just over 80%, whereas the
FIG 5 Projected time savings with BFPP compared to SOC aerobic culture. Turnaround time for the BioFire upper
respiratory panel (surrogate for BFPP) was significantly shorter (****, P  0.0001) than SOC culture for identification
(ID) of bacteria (42.2-h reduction). Likewise, the turnaround time for detection of antimicrobial resistance (AMR)
markers by BFPP was shorter (P  0.0001) than determination of antimicrobial susceptibility by standard pheno-
typic methods (56.3-h reduction). Comparisons were made via two-tail, unpaired t tests.
Evaluation of BioFire FilmArray Pneumonia Panel Journal of Clinical Microbiology
July 2020 Volume 58 Issue 7 e00343-20 jcm.asm.org 11
 on A











results from the 510(k) BFPP submission to the FDA reported an overall PPA of more
than 90% for 1829 clinical samples (14). The majority of BFPP viral targets in our study
were fully concordant with SOC; however, there were four discordant viral targets that
reduced the overall test performance, including influenza A virus, coronavirus, adeno-
virus, and parainfluenza virus. Of note, only one out of three coronaviruses detected by
SOC (detected by BioFire RP2) were also detected by BFPP. This level of discordance
among coronaviruses significantly reduced the overall PPA for viral testing. These
results are consistent with the BFPP 510(k) submission, which reported a PPA of less
than 90% for detection of coronavirus. In contrast, the BioFire RP2 assay has been
shown to perform very well for detection of coronavirus, with a PPA of 100% for
coronavirus HKU1 (n  43) (15).
It is notable that two of the discordant coronavirus results that were positive by
BioFire RP2 and negative by BFPP were negative on prior RP2 testing performed 2 h
before and 4 days before the positive SOC, suggesting that discordant results for
coronavirus may be related less to the assay and more to preanalytical factors, such as
sample quality, sample source, amount of target, or time of sampling. Sample-to-
FIG 6 Length of hospital stay and 30-day mortality grouped by test concordance between BFPP and SOC
aerobic culture for detection of S. aureus and H. influenzae. One-way analysis of variance (ANOVA)
demonstrates that length of hospital stay (left) was not significantly different for S. aureus
[F(2,195)  0.088, P  0.92] (a) or H. influenzae [F(2,195)  0.135, P  0.87] (c) detected by both BFPP and
SOC culture compared to detection by BFPP alone. Two-sided Fisher’s exact test demonstrated that
30-day mortality (right) was not significantly different for S. aureus (P  0.74) (b) or H. influenzae
(P  0.15) (d) detected by both BFPP and SOC compared detection by BFPP alone. Values inside columns
represent the number of patient deaths per x axis group that occurred within 30 days following aerobic
culture testing.
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sample variability may have contributed to discordant coronavirus results; however,
this was less of a factor in discordant detection of influenza A virus and adenovirus by
SOC methods, given that both SOC and BFPP testing were performed on the same
tracheal aspirate. A virus was detected by BFPP but not by SOC in an additional three
cases. As was the case for discordant SOC viral detections, we did not identify a feature
that clearly predicts viral test concordance. A direct comparison of BFPP with RP2 may
be warranted and would be a useful benchmark for laboratories that are considering
switching from a laboratory-developed RP2 assay for LRT specimens to the BFPP.
The BFPP assay showed high overall agreement with SOC culture for the detection
of bacteria commonly associated with pneumonia. Average PPA and NPA were very
similar to the values reported in the multisite 510(k) FDA submission (14). Only 1 of the
16 bacterial species detected by aerobic culture was negative when assayed by BFPP,
namely, Enterobacter cloacae complex, which had a PPA of 75%. There were five
off-panel bacterial species that were detected by SOC but not by BFPP, and most of
these results were only obtained once in the study, suggesting that the panel includes most
of the common causes of pneumonia. Only one such bacterium, Stenotrophomonas malto-
philia, was detected in multiple samples (n  4). The absence of Stenotrophomonas malto-
philia from the BioFire pneumonia panel is a potential concern because this multidrug-
resistant bacterium is commonly encountered among hospitalized patients and can cause
significant morbidity and mortality among immunocompromised patients (16).
These results can be compared to those described in the Curetis Unyvero LRT
application (Holzgerlingen, Germany), which received initial FDA clearance in 2018 for
qualitative detection of 19 bacterial targets and 10 resistance markers in tracheal
aspirates (17). The assay was recently expanded to include Pneumocystis jirovecii and
was cleared for use on BAL specimens as well (18). A multicenter clinical trial of the
Unyvero LRT in 603 fresh and 185 archived tracheal aspirate samples showed an overall
weighted sensitivity of 92.5% and an overall specificity of 97.4% compared to those of
culture for bacterial identification (19), and a recent retrospective comparison of the
Unyvero LRT to routine bacterial culture of BAL fluids reported an overall PPA of 96.5%
and an NPA of 99.6% (20). This study also reported a 77.8% (14/18) concordance
between resistance targets and phenotypic susceptibility testing. The BFPP has notable
differences from the Unyvero panel, including shorter turnaround time, quantitative
reporting of bacteria, and inclusion of viral targets; however, the two assays have similar
overall test performance characteristics.
Overall, our results suggest that BFPP is quite sensitive for the detection and
identification of common bacterial causes of pneumonia. A potential implementation
challenge of the assay is that it detects additional bacteria not reported by SOC culture.
This was most pronounced for S. aureus and H. influenzae, which together accounted
for more than half of bacteria detected by BFPP alone. These results are consistent with
data from the FDA clearance study for BFPP, which reported an NPA of more than 90%
for all the panel components except for S. aureus and H. influenzae, both of which had
NPAs slightly less than 90%. It was initially unclear what factors best explained the large
number of bacteria detected by BFPP alone. Our data showed that specimen type and
bacterial quantity as determined by BFPP were significant predictors of detection by
BFPP alone. The effect of bacterial quantity on test concordance is consistent with prior
work showing that PCR-based methods generally detect both viable and nonviable
bacteria as well as extracellular bacterial DNA (21, 22). This feature has been useful in
determining the etiology of meningitis following antibiotics (15); however, it may be a
liability in the setting of respiratory infection, where PCR would be expected to
overestimate bacterial count, increase the number of clinically irrelevant detections,
and drive excessive antimicrobial use. This may also have an impact on contact
isolation, especially when MRSA is detected solely by BFPP. We noted an effect of
specimen type on discordant detection of S. aureus, such that S. aureus was significantly
more likely to be detected by BFPP alone in sputum and tracheal aspirate samples. This
may be the result of criteria that are used in the clinical laboratory for reporting of
results from respiratory culture, which tend to limit the reporting of potential upper
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respiratory flora, such as S. aureus and H. influenzae, when present at low quantities in
sputum or tracheal aspirates or when found as part of normal flora in a polymicrobial
culture or low-quality specimen as indicated by few leukocytes or numerous epithelial
cells on Gram stain. While a reporting threshold is built into the BFPP, other criteria
were not used to limit BFPP reporting. These differences in reporting may explain why
nearly 100 additional bacteria were identified by BFPP alone.
BFPP showed complete agreement with SOC for detection of AMR (i.e., PPA of
100%), suggesting high assay sensitivity. NPA for mecA/C and MREJ detection was less
than 90%, due to four cases in which BFPP identified MRSA but SOC testing reported
MSSA. All of these discordant AMR results were detected in polymicrobial samples,
suggesting one of the following: (i) SOC culture workup failed to detect a mixed
specimen with co-occurring MRSA and MSSA, (ii) the detected S. aureus had an empty
SCCmec cassette, or (iii) the MRSA was below the threshold for reporting.
There was complete agreement between methods for detection of Gram-negative
AMR; however, this comparison was limited among samples with discordant bacterial
identification, including four samples with AMR markers (3 blaCTX-M and 1 blaKPC) that
were not fully characterized by SOC due to discordant bacterial identification. Results
for AMR are similar to those reported as part of the 510(k) BFPP submission to the FDA,
which likewise showed high positive agreement and modest (90%) negative agree-
ment with a comparator assay for mecA/C and MREJ detection (14). The FDA clearance
study also reported a moderately decreased positive percent agreement (90%) for
blaCTX-M detection, which is not evident in the present study, but this may also vary
depending on the prevalence, based on local epidemiology and resistance patterns. A
comparison of results with the Unyvero LRT is limited by the modest sample size in the
present study, but in general these two assays had similarly high PPA and NPA for
detection of blaCTX-M and blaKPC. The Unyvero LRT assay is also reported to have an NPA
over 90% for mecA detection, and PPA for the Unyvero LRT is slightly below 90% for
mecA detection among tracheal aspirates (17). A potential benefit of the BFPP is
detection of AMR among samples that might not otherwise be screened for resistance
markers, such as the putative blaKPC-positive sample that was identified by BFPP but
not by routine SOC testing or the 10 cases with blaCTX-M or mecA/C and MREJ on
suboptimal therapeutic regiments for these putative ARM markers. This represents a
potential opportunity for improved treatment, infection prevention, and monitoring of
antimicrobial resistance.
The results of this study demonstrate that clinical outcomes were not significantly
different regardless of whether S. aureus and H. influenzae were detected by both SOC
and BFPP or by BFPP alone. Results suggest that either the effect size was too small to
be detected in the current study, as may be the case for H. influenzae, that these
patients were treated empirically, or that patients with positive results by BFPP alone
for these bacteria do not have a true, clinically significant respiratory infection. Al-
though BFPP results were not reported to clinicians in this study, putative false-positive
results could lead to overtreatment if conveyed directly to clinicians. Our data do
suggest that health care providers can predict detections by the BioFire alone based on
semiquantitative bin value. Therefore, the reporting of bin values is critical for clinical
interpretation of results. Given the necessity of and growing emphasis on antimicrobial
stewardship, future research may explore the clinical impact of BFPP testing and
evaluate methods for conveying these results to clinicians.
This retrospective study is one of the first to evaluate the performance of the BioFire
FilmArray pneumonia panel among patients with suspected lower respiratory infection.
The limitations of this work relate to its moderate sample size, retrospective format, and
single-study-center design, which reduces generalizability. Another potential limitation
to the study is that it did not evaluate BFPP test performance with low-quality sputum
samples that were unsuitable for culture. Presumably the testing of such specimens
would result in more frequent detection of clinically insignificant respiratory microbiota
and a resultant decrease in clinical specificity. Though more data are needed regarding
the negative effect of testing low-quality sputum specimens, laboratories should
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consider adopting strategies to avoid such practices. This is consistent with the
manufacturer’s instructions suggesting that laboratories should adhere to their own
established rules for the acceptance and rejection of sputum specimens (23). Strengths
of this study include rigorous inclusion criteria, collection of detailed information on
standard-of-care testing and clinical outcomes, representation of all four seasons
during data collection, and assessment of both sputum-type and BAL-type specimens.
In conclusion, BFPP is a rapid and accurate method for detection of bacteria and
viruses from lower respiratory tract infections.
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